Key result
Acute thromboembolic events in Takotsubo cardiomyopathy are linked to higher 3-year all-cause mortality.
Why the study?
Do acute thromboembolic events on index presentation increase short-term and long-term all-cause mortality in patients with Takotsubo cardiomyopathy?
Cohort (n=114)
No
Do acute thromboembolic events on index presentation increase short-term and long-term all-cause mortality in patients with Takotsubo cardiomyopathy?
Acute thromboembolic events complicate 12.2% of Takotsubo cardiomyopathy cases—particularly in patients with elevated CRP, ST-segment elevation, and right ventricular involvement—and significantly increase 3-year all-cause mortality, supporting early anticoagulation in high-risk patients.
Answers are grounded in this paper and cite their sources.
Thromboembolic events were associated with higher 3-year mortality in Takotsubo cardiomyopathy; leaves open whether anticoagulation improves outcomes.
BACKGROUND: Several acute complications related to takotsubo cardiomyopathy (TTC) have been documented recently. However, the incidence and clinical significance of acute thromboembolic events in TTC is not well established. METHODS: A detailed investigation of the clinical characteristics and in-hospital complications of 114 consecutive patients diagnosed with TTC between January 2003 and September 2015 was carried out. This study was initiated to reveal the predictors, clinical significance, and short-term and long-term outcomes of patients with TTC associated with acute thromboembolic events on index presentation. RESULTS: The incidence of acute thromboembolic events related to TTC was around 12.2%, and these included ventricular thrombi, cerebrovascular events, retinal and brachial artery pathologies, renal, splenic, and aortic involvement. The most frequent complication on initial presentation was cardiogenic shock (20%) accompanied with pulmonary congestion (20%). Interestingly, patients experiencing thromboembolic events had higher C-reactive protein (CRP) levels as compared to the non-thromboembolic group (P = 0.02). Certain thromboembolic events were characterized by the presence of ST-segment elevation in electrocardiogram (P = 0.02). Chest pain was the primary symptom in these patients (P = 0.09). Furthermore, there was significant right ventricular involvement (as assessed by transthoracic echocardiography) in patients presenting with an acute thromboembolic event (P = 0.08). A Kaplan-Meier analysis indicated a significantly higher mortality rate over a mean follow-up of three years in the thromboembolic group than the non-thromboembolic group (log-rank, P = 0.02). CONCLUSIONS: Our results confirmed the relative common occurrence of thromboembolic events in the setting of TTC. Inflammation might play an important role in the development of thromboembolic events, and a right ventricular involvement and ST-segment elevation could be positive predictors for this occurrence. In order to circumvent the risk of a negative outcome, it is recommended that an anticoagulation therapy be initiated in all high-risk patients.
No takes yet. Share an insight, caveat, or question.
El‐Battrawy et al. (2016) conducted a cohort in Takotsubo cardiomyopathy (TTC) (n=114). Acute thromboembolic events on index presentation vs. Patients with TTC without acute thromboembolic events was evaluated on Long-term all-cause mortality over a mean follow-up of 3 years (p=0.02). Acute thromboembolic events occurred in 12.2% of Takotsubo cardiomyopathy patients and were associated with higher 3-year all-cause mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: